GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pro Medicus Ltd (ASX:PME) » Definitions » EV-to-EBITDA

Pro Medicus (ASX:PME) EV-to-EBITDA : 107.14 (As of Apr. 25, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Pro Medicus EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pro Medicus's enterprise value is A$11,138.6 Mil. Pro Medicus's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$104.0 Mil. Therefore, Pro Medicus's EV-to-EBITDA for today is 107.14.

The historical rank and industry rank for Pro Medicus's EV-to-EBITDA or its related term are showing as below:

ASX:PME' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.25   Med: 56.83   Max: 156.41
Current: 107.14

During the past 13 years, the highest EV-to-EBITDA of Pro Medicus was 156.41. The lowest was 12.25. And the median was 56.83.

ASX:PME's EV-to-EBITDA is ranked worse than
96.74% of 460 companies
in the Healthcare Providers & Services industry
Industry Median: 13.195 vs ASX:PME: 107.14

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Pro Medicus's stock price is A$107.92. Pro Medicus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.666. Therefore, Pro Medicus's PE Ratio for today is 162.04.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Pro Medicus EV-to-EBITDA Historical Data

The historical data trend for Pro Medicus's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pro Medicus EV-to-EBITDA Chart

Pro Medicus Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.10 71.85 122.35 62.00 73.46

Pro Medicus Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 62.00 - 73.46 -

Competitive Comparison of Pro Medicus's EV-to-EBITDA

For the Health Information Services subindustry, Pro Medicus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pro Medicus's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pro Medicus's EV-to-EBITDA falls into.



Pro Medicus EV-to-EBITDA Calculation

Pro Medicus's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=11138.554/103.962
=107.14

Pro Medicus's current Enterprise Value is A$11,138.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pro Medicus's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$104.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pro Medicus  (ASX:PME) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pro Medicus's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=107.92/0.666
=162.04

Pro Medicus's share price for today is A$107.92.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pro Medicus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.666.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Pro Medicus EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pro Medicus's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pro Medicus (ASX:PME) Business Description

Traded in Other Exchanges
Address
450 Swan Street, Richmond, Melbourne, VIC, AUS, 3121
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are U.S. private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.